Breast cancer is a poster child for precision medicine with advances in screening and treatment leading to a 40% reduction in breast cancer deaths. With great advances in the ability to understand the molecular underpinnings of both risk and progression of breast cancer, clinical treatment paradigms have become complex. In some instances, patients are now being over diagnosed and overtreated and there is an effort to right size some of the advances that have been made. In this seminar I will highlight how the Institute for Precision Medicine is enabling implementation of new clinical paradigms in a large healthcare system and use breast cancer as a specific use case indicating bedside to bench to bedside research. New tools and techniques for preforming systems biology analysis of breast cancers will continue to push this field forward and improve breast cancer patient outcomes.

https://leeoesterreich.org/